OEM News

Synchron Advancing its BCI Tech With NVIDIA’s Help

By: Michael Barbella

Managing Editor

Synchron is turning to NVIDIA to bolster its brain-computer interface (BCI) technology, leveraging its partners Holoscan platform to redefine the possibilities of real-time neural interaction and intelligent edge processing.

Synchron will leverage NVIDIA Holoscan to advance a next-generation implantable BCI in two key domains. First, Synchron will enhance real-time edge AI capabilities for on-device neural processing, improving signal processing and multi-AI inference technology. This will reduce system latency, bolster privacy, and provide users with a more responsive and intuitive BCI experience. NVIDIA Holoscan provides Synchron with: (i) a unified framework supporting diverse AI models and data modalities; (ii) an optimized application framework, from seamless sensor I/O integration, GPU-direct data ingestion, to accelerated computing and real-time AI, according to the company.

Second, Synchron will explore the development of a foundation model for brain inference. By processing Synchron’s neural data on an unprecedented scale, this initiative will create scalable, interpretable brain-language models with the potential to transform neuroprosthetics, cognitive expression, and seamless interaction with digital devices.

“Synchron’s vision is to scale neurotechnology to empower humans to connect to the world, and the NVIDIA Holoscan platform provides the ideal foundation,” Synchron Founder/CEO Tom Oxley, M.D., Ph.D., said. “Through this work, we’re setting a new benchmark for what BCIs can achieve.”

New York City-based Synchron is an implantable brain-computer interface company, pioneering neurotechnology designed to restore functionality for individuals with paralysis by expanding autonomy. Since 2019, Synchron has completed two human clinical trials and is now preparing for a larger-scale clinical study with a device optimized for scalable manufacturing. The company has an exclusive partnership with flexible MEMs manufacturer Aquandas, ensuring access to cutting-edge technology for devices. The BCI market represents a $400 billion opportunity (Morgan Stanley report), and Synchron is aiming to be at the forefront.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters